Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Protagonist Therapeutics Inc.

NAS: PTGX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Protagonist Therapeutics Inc.

Before the Bell

PTGX
/zigman2/quotes/205674595/composite

$

20.16

Change

-0.57 -2.75%

Volume

Volume 4

Mar 27, 2023, 4:00 a.m.

Quotes are delayed by 20 min

/zigman2/quotes/205674595/composite

Previous close

$ 20.73

$ 20.73

Change

-0.28 -1.33%

Day low

Day high

$20.41

$21.02

Open
Open: 20.74

52 week low

52 week high

$6.91

$26.00

Open

Market cap

$1.06B

Average volume

1.85M

P/E ratio

N/A

Rev. per Employee

$253,152

EPS

-2.60

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ptgx

MarketWatch News on PTGX

  5. 5 Biotech Stocks That Are Bucking the Selloff

    5:31 a.m. Jan. 19, 2022

    - Barron's Online

  6. Protagonist Therapeutics upgraded to overweight from neutral at J.P. Morgan

    6:47 a.m. Oct. 12, 2021

    - Tomi Kilgore

  8. Protagonist Therapeutics downgraded to neutral from overweight at J.P. Morgan

    6:54 a.m. Sept. 20, 2021

    - Tomi Kilgore

  9. Biotech stocks are a buy — especially these 18 picks

    2:02 p.m. March 13, 2021

    - Michael Brush

  10. Protagonist Therapeutics initiated at overweight with $35 price target at JPMorgan

    11:01 a.m. Jan. 6, 2021

    - Tonya Garcia

  11. Protagonist Therapeutics stock price target raised to $29 vs. $13 at Instinet

    8:22 a.m. May 10, 2019

    - Ciara Linnane

  12. Protagnoist Therapeutics stock price target raised to $17 from $11 at Stifel Nicolaus

    8:16 a.m. May 9, 2019

    - Tomi Kilgore

  13. Protagonist Therapeutics upgraded to buy from hold at Stifel Nicolaus

    8:16 a.m. May 9, 2019

    - Tomi Kilgore

  14. Charting the Market

    9:02 p.m. March 30, 2018

    - Barron's Online

  15. A Biotech Collapses: Is Buying Now ‘Futile’?

    5:05 p.m. March 26, 2018

    - Barrons Blogs

  17. Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus

    8:22 a.m. Jan. 29, 2018

    - Tomi Kilgore

  18. Charting the Market

    10:36 p.m. June 2, 2017

    - Barron's Online

Analyst Ratings

/news/nonmarketwatch/company/us/ptgx

Other News on PTGX

  1. 10-K: PROTAGONIST THERAPEUTICS, INC

    4:53 p.m. March 15, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. These Biotechs Were Told Their SVB Funds Were Available. It Wasn’t That Simple.

    12:38 p.m. March 15, 2023

    - The Wall Street Journal Interactive Edition

  5. 10-Q: PROTAGONIST THERAPEUTICS, INC

    6:00 p.m. Nov. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  11. 10-Q: PROTAGONIST THERAPEUTICS, INC

    5:12 p.m. Aug. 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  14. Protagonist: Too Many Red Flags

    10:45 a.m. June 8, 2022

    - Seeking Alpha

  16. 10-Q: PROTAGONIST THERAPEUTICS, INC

    5:07 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  20. FFIE, EVOK and ZY among mid-day movers

    1:11 p.m. April 26, 2022

    - Seeking Alpha

  21. Loading more headlines...
/news/pressrelease/company/us/ptgx

Press Releases on PTGX

  3. Tuesday's ETF Movers: XBI, SIL

    1:01 p.m. March 7, 2023

    - MarketNewsVideo.com

  7. Protagonist Therapeutics Reports Granting of Inducement Award

    5:05 p.m. Nov. 16, 2022

    - PR Newswire - PRF

  12. Protagonist Therapeutics Reports Granting of Inducement Award

    5:53 p.m. Sept. 20, 2022

    - PR Newswire - PRF

  14. Protagonist Therapeutics Reports Granting of Inducement Award

    7:00 a.m. July 19, 2022

    - PR Newswire - PRF

  21. Loading more headlines...

Rates »

Mortgage Equity Savings Auto
Link to MarketWatch's Slice.